ReviewFrontiers in immunology2025
Melatonin as an anti-inflammatory hormone bridging migraine relief and cancer immunity enhancement: a literature review.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prenatal road traffic noise impairs early testicular development in Sprague-Dawley offspring: pharmacological rescue by melatonin and edaravone; developmental preservation by environmental enrichment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Melatonin Supplementation Increases Oocyte Recovery and Quality Associated with Altered Follicular Steroidogenesis and Redox Status in Dairy Cows.Antioxidants (Basel, Switzerland) · 2026Article
- Melatonin in Integrative Oncology: Biological Mechanisms, Therapeutic Evidence and Implementation Strategies.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin, once relegated to the circadian periphery, has resurfaced as a pleiotropic immunomodulator capable of quelling neurogenic inflammation while invigorating antitumour defence. Migraine-and its disabling, episodic neurovascular pain-shares an "inflammatory genome", defined here as a conserved danger-response gene set (NF-κB, NLRP3, IL1B, NOS2), with the metabolic chaos that subdues cytotoxic immunity in solid cancers; both ignite NF-κB, NLRP3 and reactive-oxygen cascades that erode tissue homeostasis. Emerging evidence shows that endogenous melatonin declines precede migraine attacks, and nightly supplementation rivals first-line preventives in shrinking monthly headache burden while restoring sleep architecture. In parallel, supraphysiological pulses re-programme tumour-associated macrophages toward an iNOS-rich M1 phenotype, amplify granzyme-B output from CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.